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Second Primary Glioblastoma Multiforme Following
Autologous Hematopoietic Stem Cell Transplantation in a
Patient with Acute Myelogenous Leukemia
Introduction
Glioblastoma multiforme (GM) is the most common type of
primary brain tumor. It is found in all age groups, but is more fre-
quently encountered in the elderly. The etiology of GM is not clear,
but it is known to be associated with radiation therapy [1] and diverse
genetic defects [2,3]. Surgery, followed by standard radiotherapy
with concomitant chemotherapy, is the standard of care [4]. However,
despite aggressive treatment, the prognosis remains poor, with a
median survival of 12-15 months. This dismal prognosis is associated
with genetic abnormalities, which result in the aberrant activation or
suppression of cellular signal transduction pathways and subsequent
resistance to radiation and chemotherapy. 
GM has been previously reported in patients with hematologic
disorders who have received stem cell transplantation (SCT) after
being conditioned with chemotherapy and radiation [5], but no such
case has been reported in Korea. We encountered one 39-year-old
patient with acute myelogenous leukemia (AML), who developed
GM 61 months after autologous hematopoietic stem cell trans-
plantation (ASCT). We present this case and include a review of the
literature.
Cancer Res Treat. 2011;43(3):195-198
+  +  +  +  +  +  +  +  +  +  +  +  +  +  +  +  +  +  +  +  
+  +  +  +  +  +  +  +  +  +  +  +  +  +  +  +  +  +  +  +  
+  +  +  +  +  +  +  +  +  +  +  +  +  +  +  +  +  +  +  +
+  +  +  +  +  +  +  +  +  +  +  +  +  +  +  +  +  +  +  +  
+  +  +  +  +  +  +  +  +  +  +  +  +  +  +  +  +  +  +  +  
+  +  +  +  +  +  +  +  +  +  +  +  +  +  +  +  +  +  +  +
+  +  +  +  +  +  +  +  +  +  +  +  +  +  +  +  +  +  +  +  
+  +  +  +  +  +  +  +  +  +  +  +  +  +  +  +  +  +  +  +
+  +  +  +  +  +  +  +  +  +  +  +  +  +  +  +  +  +  +  +
+  +  +  +  +  +  +  +  +  +  +  +  +  +  +  +  +  +  +  +  
+  +  +  +  +  +  +  +  +  +  +  +  +  +  +  +  +  +  +  +
+  +  +  +  +  +  +  +  +  +  +  +  +  +  +  +  +  +  +  +
+  +  +  +  +  +  +  +  +  +  +  +  +  +  +  +  +  +  +  +
+  +  +  +  +  +  +  +  +  +  +  +  +  +  +  +  +  +  +  +  
+  +  +  +  +  +  +  +  +  +  +  +  +  +  +  +  +  +  +  +
+  +  +  +  +  +  +  +  +  +  +  +  +  +  +  +  +  +  +  +
+  +  +  +  +  +  +  +  +  +  +  +  +  +  +  +  +  +  +  +
+  +  +  +  +  +  +  +  +  +  +  +  +  +  +  +  +  +  +  +
+  +  +  +  +  +  +  +  +  +  +  +  +  +  +  +  +  +  +  +
Glioblastoma multiforme (GM) is one of the most aggressive primary brain tumors, and has a
poor prognosis despite intensive treatment. GM is also the most malignant astrocytoma, with
histopathological features that include cellular polymorphism, rapid mitotic activity,
microvascular proliferation, and necrosis. The causes of GM remain obscure, but several
reports have shown associations between GM and genetic alterations and radiation
exposure. Furthermore, high-dose chemotherapy/radiotherapy with autologous stem cell
transplantation  is increasingly being used to treat patients with leukemia, and patients who
undergo stem cell transplantation have a higher risk of solid tumor cancer development later
in life. Based on these associations, we discuss GM development in a patient who
underwent chemoradiotherapy conditioning prior to stem cell transplantation.
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1   Present illness
A 39-year-old male was admitted to our hospital with loss of
memory for 10 months. The patient was diagnosed with AML in
February 2001 and underwent ASCT in October 2001. No specific
complications had been detected after transplantation until the
patient visited our hospital with a chief complaint of continued loss
of memory since the end of 2005. The patient underwent a brain
computed tomography scan and surgery was planned based on a
suspicion of GM. However, the patient suffered rapid memory loss 3
days before hospitalization. Exacerbation of brain edema was
suspected and he was admitted to the emergency room.
2   Past medical history and medication
The patient underwent induction therapy consisting of idarubicin
(IDA, 12 mg/m
2/day), N4-behenoyl-1-ǰ -D-arabinofuranosylcytosine
(BH-AC, 300 mg/m
2/day), and augmentation (BH-AC, 400
mg/m
2/day). In May 2001, he received the first consolidation therapy
(IDA, 12 mg/m
2/day; BH-AC, 300 mg/m
2/day), and in July he under-
went a second consolidation therapy (mitoxantrone, 12 mg/m
2/day;
etoposide phosphate, 100 mg/m
2/day). In October of the same year,
he received ASCT after being conditioned with cytarabine (Ara-C,
1.5 g/m
2/day) for 3 days, and receiving total body irradiation (TBI,
10 Gy for 3 days), and melphalan (100 mg/m
2/day) for 1 day. He
was subsequently monitored, but no transplantation-related symptoms
were noted. Memory loss, however, developed at the end of 2005,
which prompted his visit to our Internal Medicine Department.
3   Physical examination
Vital signs at patient presentation were: blood pressure, 135/80 mm
Hg; pulse, 93/min; respiration rate, 20/min; and body temperature,
37.1. There was no sign of acute illness. A head and neck exami-
nation showed no signs of pale conjunctiva, pharyngeal injection, or
lymph node enlargement. A chest examination showed normal lung
and heart sounds, an abdominal examination showed no signs of an
enlarged liver or spleen, tenderness, or rebound tenderness, and a
neurological examination showed that cerebral nerves, motor nerves,
and sensory nerves were all normal.
4   Laboratory results
A complete blood count showed a total white blood cell count of
15.210
9/L (neutrophils, 84.6%; lymphocytes, 13.5%; and monocytes,
1.8%), hemoglobin 14.5 g/dL, and platelets 19510
9/L. All
additional blood chemistry results were within the normal range.
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Fig. 1. Brain magnetic resonance imaging. An irregular and nodular enhancing lobulated lesion of -5.53.63.2 cm size is noted in the parieto-
occipital region extending splenium of corpus callosum and medial temporal lobe. This lesion has an internal cystic portion and is associated with
surrounding edema. Leptomeningeal enhancement is noted in both the lateral, 4th ventricle and perimesencephalic cystern, suggesting
leptomeningeal seeding. There is no evidence of focal stenotic lesion or aneurismal dilatation.5 Radiological results
Brain magnetic resonance imaging (MRI) conducted before his
visit to the hospital revealed irregular, leaf-like lesions (5.53.6
3.2 cm) in the parietal and occipital lobes, over medial temporal lobes
and the splenium of the corpus callosum. The lesion contained internal
cysts and was associated with edema. MRI also revealed meningeal
metastasis (Fig. 1).
6   Pathological results
Pathologic findings of malignant astrocytes confirmed GM grade
4 according to World Health Organization (WHO) criteria. Additional
microscopic analysis showed prominent cellularity, moderate cyto-
logical pleomorphism, 5-6 mitoses per 10 high-power fields, and
endothelial cell proliferation and necrosis. An immunohistochemical
examination confirmed a positive reaction for glial fibrillary acidic
protein, the intermediate filament specifically generated in central
nervous system (CNS) astrocytoma. Furthermore, 75% of cells were
positive for Ki-67 protein, nuclear and nucleolar proteins, which are
found within nuclei only during the interphase stage of cell division,
and are associated with cell proliferation. Positive reactions were also
observed for O6-methylguanine-DNA methyltransferase (MGMT),
and for epidermal growth factor receptor (EGFR).
7   Treatment and clinical progress
On the 5th day of hospitalization, frameless neuronavigation
guided craniotomy was performed with open biopsy for pathologic
confirmation, and concomitant chemoradiotherapy (180 cGy/day
radiation plus temozolomide 75 mg/m
2/day) was maintained from
day 11 until day 19. Following 2 months of hospitalization, the patient
was discharged without completing a second maintenance therapy
because he refused further chemoradiotherapy. Four months after
diagnosis of GM, he reported sudden dyspnea and was treated in the
intensive care unit. He succumbed to acute respiratory distress synd-
rome, which developed from Pneumocystis carinii pneumonia, despite
the administration of trimethoprime/sulfamethoxazole for 11 days.
Discussion
The use of SCT to treat hematologic disorders is increasing, and
transplantation-conditioning regimens usually incorporate chemo-
therapy and TBI. However, these two treatment modalities are
carcinogenic and their usages have generated increasing interest in
their association with secondary tumor development after transplan-
tation. Furthermore, several studies have been conducted on the
incidence of secondary tumor development and the risk factors
involved [6,7]. The incidence of solid tumors in patients who received
SCT (including autologous and allogeneic) has been reported to be
8.3-fold greater than in the normal population at 10 year post-SCT,
and incidences in the brain and other parts of the CNS were found to
be 7.6-fold greater. Secondary solid tumors that form after ASCT
are likely to be directly influenced by high-dose chemotherapy and
TBI, and the development of GM after SCT is no exception [8].
Alkylating anti-cancer agents are known to be capable of generating
secondary tumors after being used for treatment of a primary cancer.
The alkylating agent melphalan is frequently used in conditioning
regimens, and the incidence of secondary tumor development after
treatment with melphalan is 7-fold greater than normal, and is 10-
fold greater after melphalan/TBI conditioning. This finding concurs
with a previous report that the most significant risk factor for the
development of a secondary tumor is the combined use of radio-
therapy and chemotherapy [9]. Furthermore, this risk is much higher
for cancers of the skin, brain, breast, or thyroid gland [10].
According to the assessment based on the Naranjo Causality
Scale [11], which addresses the strength of the relationship between
a drug and a suspected adverse reaction, our case had a total score of
6, based on the following scale: (definite causal relationship when
the total score is 9, probable relationship when between 5-8, possible
relationship when between 1-4, and doubtful relationship for a total
score of 0). The score of 6 was calculated based on responses to the
following four questions: (Are there previous conclusive reports on
reaction? Yes=+1; Did the adverse event appear after the suspected
drug was administered? Yes=+2; Are there alternative causes that
could, on their own, have caused the reaction? No=+2; Was the re-
action more severe when the dose was increased, or less severe
when the dose was decreased? Yes=+1).
According to this scale, in our case, an association between
melphalan treatment and the incidence of GM was likely. Additionally,
in a previous study, based on multivariable analysis of TBI as a
potential factor for secondary tumor generation, the incidence of a
secondary tumor among patients with a hematopoietic disorder who
received TBI was 3.9-fold greater than that of patients who did not
receive TBI [12]. In the described case, 10 Gy of radiation was ad-
ministered over 3 days, which would have increased the risk of GM
development based on the above mentioned analysis [13]. Accordingly,
in our patient, chemotherapy or TBI after SCT may have generated
the secondary solid tumor and their simultaneous application would
have increased the risk of a second malignancy. 
Secondary glioblastoma is distinct from primary glioblastoma,
and develops as a result of different genetic alterations [14]. Because
the patient demonstrated EGFR amplification, which is a genetic
alternation typical of primary GM, the proper diagnosis was “second
primary GM developing after chemoradiotherapy,” rather than se-
condary GM. Despite their distinctive pathogeneses, their clinical
courses and treatments are similar to those of primary disease in
terms of widespread invasion and resistance to therapy. Important
prognostic factors include the type of surgery and adjuvant chemo-
therapy [15]. Several studies reported that at least 4 cycles of radio-
therapy plus adjuvant chemotherapy (especially, temozolomide) are
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generating a secondary tumor, regular examinations are required to
detect minute physical changes in patients who undergo SCT.
Second primary GM occurring in a 39-year-old male patient with
AML who had undergone ASCT may have been caused by melphalan
or TBI. A similar case has not been previously reported in Korea,
and thus, we present this case and include a literature review.
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